Sino-Argi Leading Biosciences (603970) - Net Assets
Based on the latest financial reports, Sino-Argi Leading Biosciences (603970) has net assets worth CN¥1.78 Billion CNY (≈ $260.78 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.57 Billion ≈ $960.83 Million USD) and total liabilities (CN¥4.78 Billion ≈ $700.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603970 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.78 Billion |
| % of Total Assets | 27.14% |
| Annual Growth Rate | 16.34% |
| 5-Year Change | 34.92% |
| 10-Year Change | 300.6% |
| Growth Volatility | 24.5 |
Sino-Argi Leading Biosciences - Net Assets Trend (2012–2025)
This chart illustrates how Sino-Argi Leading Biosciences's net assets have evolved over time, based on quarterly financial data. See Sino-Argi Leading Biosciences (603970) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Sino-Argi Leading Biosciences (2012–2025)
The table below shows the annual net assets of Sino-Argi Leading Biosciences from 2012 to 2025. For live valuation and market cap data, see market cap of Sino-Argi Leading Biosciences.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.73 Billion ≈ $252.90 Million |
+2.71% |
| 2024-12-31 | CN¥1.68 Billion ≈ $246.23 Million |
+5.55% |
| 2023-12-31 | CN¥1.59 Billion ≈ $233.27 Million |
+7.38% |
| 2022-12-31 | CN¥1.48 Billion ≈ $217.23 Million |
+15.90% |
| 2021-12-31 | CN¥1.28 Billion ≈ $187.44 Million |
+12.02% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.32 Million |
+9.48% |
| 2019-12-31 | CN¥1.04 Billion ≈ $152.84 Million |
+9.13% |
| 2018-12-31 | CN¥957.07 Million ≈ $140.05 Million |
+10.47% |
| 2017-12-31 | CN¥866.35 Million ≈ $126.77 Million |
+100.81% |
| 2016-12-31 | CN¥431.42 Million ≈ $63.13 Million |
+25.21% |
| 2015-12-31 | CN¥344.56 Million ≈ $50.42 Million |
+18.63% |
| 2014-12-31 | CN¥290.44 Million ≈ $42.50 Million |
+10.57% |
| 2013-12-31 | CN¥262.68 Million ≈ $38.44 Million |
+8.71% |
| 2012-12-31 | CN¥241.63 Million ≈ $35.36 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sino-Argi Leading Biosciences's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 930.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥906.25 Million | 57.50% |
| Other Components | CN¥669.78 Million | 42.50% |
| Total Equity | CN¥1.58 Billion | 100.00% |
Sino-Argi Leading Biosciences Competitors by Market Cap
The table below lists competitors of Sino-Argi Leading Biosciences ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Longxing Chemical Stock Co Ltd
SHE:002442
|
$403.59 Million |
|
Smcp SAS
PA:SMCP
|
$403.85 Million |
|
Panoro Energy ASA
OL:PEN
|
$403.92 Million |
|
Xinxiang Tuoxin Pharmaceutical Co.Ltd.
SHE:301089
|
$404.05 Million |
|
Quess Corp Limited
NSE:QUESS
|
$403.53 Million |
|
TangYuan Electric
SHE:300789
|
$403.52 Million |
|
Guangxi Fenglin Wood Industry Group Co Ltd
SHG:601996
|
$403.50 Million |
|
Jiangsu Lidao New Material Co Ltd Class A
SHG:603937
|
$403.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sino-Argi Leading Biosciences's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,520,445,416 to 1,576,022,928, a change of 55,577,512 (3.7%).
- Net income of 172,533,800 contributed positively to equity growth.
- Dividend payments of 143,106,635 reduced retained earnings.
- Other comprehensive income decreased equity by 156,624,722.
- Other factors increased equity by 182,775,069.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥172.53 Million | +10.95% |
| Dividends Paid | CN¥143.11 Million | -9.08% |
| Other Comprehensive Income | CN¥-156.62 Million | -9.94% |
| Other Changes | CN¥182.78 Million | +11.6% |
| Total Change | CN¥- | 3.66% |
Book Value vs Market Value Analysis
This analysis compares Sino-Argi Leading Biosciences's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 7.56x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.36 | CN¥10.26 | x |
| 2013-12-31 | CN¥1.31 | CN¥10.26 | x |
| 2014-12-31 | CN¥1.21 | CN¥10.26 | x |
| 2015-12-31 | CN¥1.50 | CN¥10.26 | x |
| 2016-12-31 | CN¥1.71 | CN¥10.26 | x |
| 2017-12-31 | CN¥3.78 | CN¥10.26 | x |
| 2018-12-31 | CN¥3.22 | CN¥10.26 | x |
| 2019-12-31 | CN¥3.56 | CN¥10.26 | x |
| 2020-12-31 | CN¥3.81 | CN¥10.26 | x |
| 2021-12-31 | CN¥4.36 | CN¥10.26 | x |
| 2022-12-31 | CN¥4.90 | CN¥10.26 | x |
| 2023-12-31 | CN¥5.36 | CN¥10.26 | x |
| 2024-12-31 | CN¥5.66 | CN¥10.26 | x |
| 2025-12-31 | CN¥5.86 | CN¥10.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sino-Argi Leading Biosciences utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.95%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.53%
- • Asset Turnover: 2.29x
- • Equity Multiplier: 3.12x
- Recent ROE (10.95%) is below the historical average (18.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 25.33% | 2.59% | 1.74x | 5.63x | CN¥33.56 Million |
| 2013 | 29.92% | 2.76% | 1.50x | 7.20x | CN¥45.75 Million |
| 2014 | 32.98% | 2.81% | 1.47x | 8.00x | CN¥56.24 Million |
| 2015 | 29.13% | 2.73% | 1.29x | 8.30x | CN¥57.96 Million |
| 2016 | 23.68% | 2.40% | 1.32x | 7.48x | CN¥47.21 Million |
| 2017 | 11.53% | 2.58% | 1.26x | 3.55x | CN¥12.01 Million |
| 2018 | 13.34% | 3.09% | 1.44x | 2.99x | CN¥28.93 Million |
| 2019 | 12.43% | 2.74% | 1.59x | 2.87x | CN¥23.27 Million |
| 2020 | 12.92% | 1.99% | 1.65x | 3.92x | CN¥29.92 Million |
| 2021 | 14.54% | 1.93% | 1.86x | 4.05x | CN¥53.20 Million |
| 2022 | 15.95% | 1.80% | 1.87x | 4.74x | CN¥78.48 Million |
| 2023 | 15.62% | 2.15% | 1.74x | 4.17x | CN¥80.89 Million |
| 2024 | 13.38% | 1.92% | 1.89x | 3.68x | CN¥51.33 Million |
| 2025 | 10.95% | 1.53% | 2.29x | 3.12x | CN¥14.93 Million |
Industry Comparison
This section compares Sino-Argi Leading Biosciences's net assets metrics with peer companies in the Agricultural Inputs industry.
Industry Context
- Industry: Agricultural Inputs
- Average net assets among peers: $2,671,873,882
- Average return on equity (ROE) among peers: 9.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sino-Argi Leading Biosciences (603970) | CN¥1.78 Billion | 25.33% | 2.68x | $403.57 Million |
| Hubei Yihua Chemical Industry Co Ltd (000422) | $13.55 Billion | 6.56% | 2.40x | $2.09 Billion |
| Nanjing Red Sun Co Ltd (000525) | $2.95 Billion | 13.14% | 1.46x | $831.95 Million |
| ADAMA Ltd (000553) | $1.12 Billion | 2.13% | 0.80x | $1.84 Billion |
| Grand Industrial Holding Co Ltd (000626) | $12.65 Million | 0.00% | 2.96x | $517.47 Million |
| Sichuan Meifeng Chemical Industry Co Ltd (000731) | $1.27 Billion | 19.58% | 0.78x | $440.10 Million |
| Qinghai Salt Lake Industry Co.Ltd (000792) | $687.57 Million | 11.78% | 0.49x | $23.04 Billion |
| Asia Potash International Investment Guangzhou Co Ltd (000893) | $137.96 Million | 36.31% | 2.09x | $5.53 Billion |
| Hubei Xinyangfeng Fertilizer Co Ltd (000902) | $417.86 Million | 0.76% | 1.26x | $2.23 Billion |
| Sichuan Lutianhua Co Ltd (000912) | $6.38 Billion | 1.20% | 0.60x | $782.42 Million |
| Guangxi Hechi Chemical Co Ltd (000953) | $194.14 Million | 5.16% | 1.04x | $297.88 Million |
About Sino-Argi Leading Biosciences
Sino-Agri Leading Biosciences Co.,Ltd engages in pesticide distribution in China and internationally. The company sells technical materials, formulations, and related products. It also provides plant protection technology services; and crop health solutions, including technical guidance, application demonstration, and processing and packaging of plant protection products. In addition, the company… Read more